Ibrutinib is a prototypical irreversible Bruton's tyrosine kinase (BTK) inhibitor. This study (RESONATE), together with {1-3}, led to its approval for use in all patients with chronic lymphocytic leukemia (CLL). Byrd et al. compared ibrutinib to ofatumumab in 391 patients with relapsed or refractory CLL or small lymphocytic lymphoma and showed large improvements in overall response rates and both progression-free survival and overall survival. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Prithviraj Bose and Varsha Gandhi.